Many agree that disability inclusion in clinical trials is a worthy pursuit, but the historical significance and future impact of pursuing this goal is relatively unexplored. Here, we peel back the layers of this vital mission.

We take a look at the value of patient data, how it can impact Pharma and to what extent it could benefit the industry.

For Pride Month 2022, Prime Patient investigate how Pharma can build stronger, more productive relationships with the LGBTQIA+ community 

This Pride Month, Prime Patient takes a close look at the health inequity faced by the transgender community, and what we can do about it. 

This month, the results of the 2021 PatientView corporate reputation survey were released. With insights from 240 US patient groups, a number of key findings were reported; here, we take a closer look.

Prime Patient team up with Jess Duggan from the SynGAP Research Fund to better understand what this advocacy group wants Pharma to know this Developmental Disabilities Awareness Month.

Prime Patient collaborate with award-winning advocate Trishna Bharadia to explore how industry can better engage with people living with multiple sclerosis (PwMS) this MS Awareness Month. 

Patient advocacy and engagement are important no matter the disease area, whether it’s a common condition or one that few have heard of. Following the recent celebration of Rare Disease Day, let’s take a closer look at patient engagement in rare mutation cancers. 

In the spirit of Rare Disease Day, which was celebrated on 28 February, we’re looking at the importance of patient engagement in lysosomal storage disorders (LSDs).

Medical publishing is evolving beyond plain language summaries to provide insightful, patient-centred resources to change the course of pharmaceutical research for the better. For patients with rare diseases especially, this could be just what the doctor ordered, writes Olivia Kersey, Patient Engagement Strategist with Prime Patient.

Emma Sutcliffe, SVP Patient Insights and Solutions, Prime Patient shares her reflections about whether the pandemic has helped or hindered patient engagement and research for rare diseases.